CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3

Cancer Research

Volumn 62, Issue 16, 2002, Pages 4599-4604

  Kochetkova, Marina ^a   McKenzie, Olivia L D ^a   Bais, Anthony J ^a   Martin, Julie M ^a   Secker, Genevieve A ^b   Seshadri, Ram ^c   Powell, Jason A ^a   Hinze, Susan J ^b   Gardner, Alison E ^a   Spendlove, Hayley E ^a   O’Callaghan, Nathan J ^a   Cleton Jansen, Anne Marie ^d   Cornelisse, Cees ^d   Whitmore, Scott A ^b   Crawford, Joanna ^b,d   Kremmidiotis, Gabriel ^b   Sutherland, Grant R ^a   Callen, David F ^b  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b Bionomics Ltd   (United States)

^c FLINDERS UNIVERSITY   (Australia)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CHROMOSOME 16P; CYTOGENETICS; GENE REPRESSION; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPORTER GENE; RETROVIRUS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; VIRUS INFECTION;

BREAST NEOPLASMS; CELL DIVISION; CHROMOSOMES, HUMAN, PAIR 16; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; PHOSPHOPROTEINS; PROTEIN BIOSYNTHESIS; PROTEINS; REPRESSOR PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0037102152     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Genetic alterations in breast cancer
2. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization
3. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type
4. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions
5. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: Different pathways in ductal and lobular breast cancer?
6. Mutant E-cadherin breast cancer cells do not display constitutive Wnt signalling
7. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family
8. ETO fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDACl complex
9. Nuclear import and subnuclear localization of the proto-oncoprotein ETO (MTG8)
10. MTG8 proto-oncoprotein interacts with the regulatory subunit of type 11 cyclic AMP-dependent protein kinase in lymphocytes
11. Absolute quantification of mRNA using real time reverse transcription polymerase chain reaction assay
12. Target and signal amplification: Approaches to increase the sensitivity of in situ hybridization
13. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells
14. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines
15. Heterogeneity in breast cancer and the problem of relevance of findings
16. Loss of heterozygosity of chromosome 16 in breast cancer cell lines
17. A high degree of chromosomal instability at 13q14 in cutaneous squamous cell carcinomas: Indication for a role of a turnout suppressor gene other than Rb
18. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo
19. Cancer epigenetics comes of age
20. Frequent loss of expression without sequence mutations of the DCC gene in primary gastric cancer
21. ETO a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain
22. Multiple regions of ETO cooperate in transcriptional repression